drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T)
drug_description
Autologous gene‑engineered T cells expressing a mesothelin‑targeted CAR and providing local anti‑PD‑1 activity to block PD‑1/PD‑L1 signaling, enhancing T‑cell activation, cytotoxicity, and persistence in PD‑L1–positive, mesothelin‑expressing tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a mesothelin-targeted chimeric antigen receptor that recognizes and kills mesothelin-positive tumor cells, while concurrently delivering local anti–PD-1 activity to block PD-1/PD-L1 signaling, enhancing T-cell activation, cytotoxicity, and persistence in the tumor microenvironment.
drug_name
αPD1‑MSLN‑CAR T cells
nct_id_drug_ref
NCT05944185